NCT00313053View on ClinicalTrials.gov

Study of mAb 216 With Chemotherapy for Treatment of Pediatric Relapsed or Refractory B-progenitor Acute Lymphoblastic Leukemia

PHASE1TerminatedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

September 30, 2004

Primary Completion Date

April 30, 2008

Study Completion Date

July 31, 2008

Conditions
Leukemia, Lymphocytic, AcuteLeukemiaAcute Lymphoid Leukemia (ALL)
Interventions
DRUG

Human mAb 216

Two treatment courses of mAb infusion will be given, with the same dose of antibody administered on Day 0 and on Day 7.

DRUG

Vincristine

Vincristine 1.5 mg/m2/dose (max dose = 2 mg) IVP on weekly x 4 doses (Days 7, 14, 21, 28)

Trial Locations (1)

94305

Stanford University School of Medicine, Stanford

Sponsors

Lead Sponsor

Clare Twist
All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

lead

Clare Twist

OTHER